EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Preclinical and first-in-human evidence of 4-hydroxybenzoic acid for mitochondrial COQ2 deficiency

Felix Distelmaier iD, Julia Corral-Sarasa, Laura Jiménez-Sánchez, María Elena Díaz-Casado, Melanie Rohmann, Annette Seibt, Diran Herebian, Sander H J Smits, Juliane Münch, Ertan Mayatepek, Jörg Breitkreutz, Ralf A Husain iD und 3 weitere

Brain · 2026

DOI: 10.1093/brain/awaf334 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Brain, 2026. Verfasst von Felix Distelmaier und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich-Heine-University Düsseldorf, Düsseld…. Hauptthemen laut MEDLINE: Ubiquinone, Parabens, Ataxia, Mitochondrial Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Innovación y Universidades, European Regional Development Fund, Universidad de Granada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary coenzyme Q (CoQ) deficiency is a mitochondrial disorder with variable clinical presentation and limited response to standard CoQ10 supplementation. Recent studies suggest that 4-hydroxybenzoic acid (4-HBA), a biosynthetic precursor of CoQ, may serve as a substrate enhancement treatment in cases caused by pathogenic variants in COQ2, a gene encoding a key enzyme in CoQ biosynthesis. However, it remains unclear whether 4-HBA is required throughout life to maintain health, whether it offers advantages over CoQ10 treatment, and whether these findings are translatable to humans. Here, we demonstrate that lifelong 4-HBA supplementation in a murine model carrying the pathogenic Coq2A252V variant is well tolerated and prevents the onset of mitochondrial encephalopathy. In contrast, withdrawal of 4-HBA leads to progressive neurological decline. Notably, while conventional CoQ10 supplementation transiently ameliorated cardiac dysfunction, it failed to prevent fatal neurological deterioration. Guided by these preclinical findings, we initiated a first-in-human individual therapeutic trial with 4-HBA in a 3-year-old boy with genetically confirmed primary CoQ10 deficiency due to compound heterozygous pathogenic COQ2 variants. The patient presented with a Leigh-like syndrome characterized by bilateral brain lesions, developmental delay, muscular hypotonia, failure to thrive, lactic acidosis and steroid-resistant nephrotic syndrome. Despite high-dose oral CoQ10 supplementation, clinical response had been minimal. Prior to clinical application, patient-derived fibroblasts were treated in vitro with 4-HBA, resulting in a marked increase in endogenous CoQ10 levels. Following the initiation of oral 4-HBA treatment, the patient experienced rapid and sustained remission of proteinuria, improved renal hyperfiltration and a gradual increase in serum CoQ10 concentrations. No adverse effects were observed during a 6-month follow-up. Clinically, the patient showed notable improvements in motor skills, language acquisition, cognitive alertness and overall development, accompanied by significant gains in growth and nutritional status. Clinical recovery was also reflected by improved scores on the Newcastle Paediatric Mitochondrial Disease Scale. These findings support 4-HBA as a promising targeted metabolic treatment for COQ2-related CoQ deficiency and highlight the need for further clinical investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UbiquinoneParabensAtaxiaMitochondrial DiseasesAlkyl and Aryl TransferasesHumansAnimalsMiceMaleChild, PreschoolDisease Models, AnimalMitochondriaMuscle Weakness

Stichwörter der Autor:innen

4-hydroxybenzoic acidCOQ2coenzyme Q deficiencymitochondrial diseasespharmacological therapytherapeutic trial

Substanzen

UbiquinoneParabens4-hydroxybenzoic acidAlkyl and Aryl Transferases4-hydroxybenzoate polyprenyltransferase

Autor:innen und Institutionen

  • Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich-Heine-University Düsseldorf, Düsseldorf 40225, Germany.
  • MetabERN: European Reference Network for Rare Hereditary Metabolic Disorders, Health Care Provider Düsseldorf, Düsseldorf 40225, Germany.
  • West German Center for Child and Adolescent Health, Partner Site Düsseldorf, Düsseldorf 40225, Germany.
  • Departamento de Fisiología, Facultad de Medicina, Universidad de Granada, Granada 18016, Spain.
  • Instituto de Investigación Biosanitaria ibs.Granada, Granada 18016, Spain.
  • Department of Pediatrics, Pediatric Nephrology, Jena University Hospital, Jena 07747, Germany.

ORCID-Profile: Felix Distelmaier, Ralf A Husain, Luis C López

Förderung

  • Ministerio de Ciencia, Innovación y Universidades
  • European Regional Development Fund
  • Universidad de Granada
  • Ministerio de Universidades
  • Deutsche Forschungsgemeinschaft
  • 'Elterninitiative Kinderkrebsklinik e.V.'
  • ‘Elterninitiative Kinderkrebsklinik e.V.’

Zitieren

APA

Distelmaier, F., Corral-Sarasa, J., Jiménez-Sánchez, L., Díaz-Casado, M. E., Rohmann, M., Seibt, A., Herebian, D., Smits, S. H. J., Münch, J., Mayatepek, E., Breitkreutz, J., Husain, R. A., López-Herrador, S., González-García, P., & López, L. C. (2026). Preclinical and first-in-human evidence of 4-hydroxybenzoic acid for mitochondrial COQ2 deficiency. Brain. https://doi.org/10.1093/brain/awaf334

Vancouver

Distelmaier F, Corral-Sarasa J, Jiménez-Sánchez L, Díaz-Casado ME, Rohmann M, Seibt A, et al. Preclinical and first-in-human evidence of 4-hydroxybenzoic acid for mitochondrial COQ2 deficiency. Brain. 2026. doi:10.1093/brain/awaf334

BibTeX
@article{Distelmaier2026,
  author = {Distelmaier, Felix and Corral-Sarasa, Julia and Jiménez-Sánchez, Laura and Díaz-Casado, María Elena and Rohmann, Melanie and Seibt, Annette and Herebian, Diran and Smits, Sander H J and Münch, Juliane and Mayatepek, Ertan and Breitkreutz, Jörg and Husain, Ralf A and López-Herrador, Sergio and González-García, Pilar and López, Luis C},
  title = {Preclinical and first-in-human evidence of 4-hydroxybenzoic acid for mitochondrial COQ2 deficiency},
  journal = {Brain},
  year = {2026},
  doi = {10.1093/brain/awaf334}
}
Kostenlos starten →